Lucia Gambuzza

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.

Isa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Christina Y. Weng, MD, MBA, FASRS; Michael A. Singer, MD, and Isa S. K. Mohammed, MD, point to early retinal care, corticosteroid training, and regulation and waste.

Johnson & Johnson spotlights contrast-driven cataract outcomes at AAO 2026, touting TECNIS PureSee/Odyssey data, 1M implants, and SmartLOAD injector sustainability.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation choice.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Anat Galor, MD, MSPH, discusses subtyping dry eye, emerging diagnostic tools, and when to consider oral neuromodulation.

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.

Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

Vaidehi Dedania, MD, discussed surgical advances, candidates, and how far whole eye transplant is from clinical use.

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic exposure.

Anat Galor, MD, MSPH, explains how to tell whether dry eye pain stems from the nerves or the tear film and how to target it.

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye disease.

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.

Anjum F. Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

Liangbo Shen, MD, discussed unmet needs in geographic atrophy and how implants could ease treatment burden.

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight.

Timothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.